Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Renal transplantation in 2016

Novel approaches to improve recipient and allograft outcomes

Nature Reviews Nephrology volume 13, pages 73–74 (2017)Cite this article

Subjects

Kidney transplantation was the focus of numerous publications in 2016. Key studies demonstrated a survival advantage of HLA-incompatible kidney transplantation and suggested that novel approaches such as co-stimulation blockade using belatacept and treatment of antibody-mediated rejection using a C1 esterase inhibitor might prove to be future game changers.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Potential strategy for belatacept-based immunosuppression in de novo kidney transplant recipients.

References

  1. Ferrari, P. et al. Kidney paired donation: principles, protocols and programs. Nephrol. Dial. Transplant. 30, 1276–1285 (2016).

    Article  Google Scholar 

  2. Orandi, B. J., Montgomery, R. A. & Segev, D. L. Kidney transplants from HLA-incompatible live donors and survival. N. Engl. J. Med. 375, 288–289 (2016).

    PubMed  Google Scholar 

  3. Montgomery, R. A. et al. Plasma-derived C1 esterase inhibitor for acute antibody-mediated rejection following kidney transplantation: results of a randomized double-blind placebo-controlled pilot study. Am. J. Transplant. 16, 3468–3478 (2016).

    Article  CAS  PubMed  Google Scholar 

  4. Sautenet, B. et al. One-year results of the effects of rituximab on acute antibody-mediated rejection in renal transplantation: RITUX ERAH, a multicenter double-blind randomized placebo-controlled trial. Transplantation 100, 391–399 (2016).

    Article  CAS  PubMed  Google Scholar 

  5. Vincenti, F. et al. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am. J. Transplant. 12, 210–217 (2012).

    Article  CAS  PubMed  Google Scholar 

  6. Pestana, J. O. et al. Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am. J. Transplant. 12, 630–639 (2012).

    Article  CAS  PubMed  Google Scholar 

  7. Vincenti, F. et al. Belatacept and long-term outcomes in kidney transplantation. N. Engl. J. Med. 374, 2600–2601 (2016).

    Article  PubMed  Google Scholar 

  8. Gatault, P. et al. Reduction of extended-release tacrolimus dose in low immunological risk kidney transplant recipients increases risk of rejection and appearance of DSA — a randomized study. Am. J. Transplant. http://dx.doi.org/10.1111/ajt.14109 (2016).

  9. Hricik, D. E. et al. Adverse outcomes of tacrolimus withdrawal in immune-quiescent kidney transplant recipients. J. Am. Soc. Nephrol. 26, 3114–3122 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinique de Néphrologie, Unité de Transplantation Rénale, Centre Hospitalier Universitaire, Grenoble-Alpes, Grenoble, France

    Paolo Malvezzi & Lionel Rostaing

Authors
  1. Paolo Malvezzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lionel Rostaing
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lionel Rostaing.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Malvezzi, P., Rostaing, L. Novel approaches to improve recipient and allograft outcomes. Nat Rev Nephrol 13, 73–74 (2017). https://doi.org/10.1038/nrneph.2016.190

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneph.2016.190

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing